MRTNZ

MRTNZ Investment Office · The 360 Vantage

AMGN · NASDAQ-GS

Amgen Inc.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

Reference price$384.65As of Jul 30, 2026
Market capitalization$208B
52-week range$269.77–$398.00
QQQ portfolio weight1.00%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$300.00-22.0% vs. reference
Average$358.91-6.7% vs. reference
High$427.00+11.0% vs. reference
10 Buy10 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS$5.609 estimates
Expected range$5.43–$5.84Low to high EPS
Dec 2026$22.31Street EPS consensus
Dec 2027$23.86Street EPS consensus
Dec 2028$24.32Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+10.0% YoY$36.75B$33.42B
Operating income$9.08B$7.26B
Net income$7.71B$4.09B
Operating cash flow$9.96B$11.49B
Capital expenditures($1.86B)($1.1B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Amgen (AMGN) Stock Moves -1.44%: What You Should Know

Zacks

Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline

The Motley Fool

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official QQQ-tracking holdings →

Facts, estimates, and scenario analysis are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Eligibility, consensus, and price data can change. This page is illustrative research, not investment advice.